Junshi Biosciences and Coherus Announce Toripalimab First-Line Nasopharyngeal Carcinoma Clinical Data to be Showcased in Plenary Session at 2021 ASCO Annual Meeting
April 29, 2021 07:30 ET
|
Coherus BioSciences, Inc.
SHANGHAI, China, and REDWOOD CITY, Calif., April 29, 2021 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd. (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and Coherus BioSciences,...
Coherus Announces Toripalimab Achieved Primary Endpoints of Progression Free Survival and Overall Survival in Interim Analysis of Phase 3 Clinical Trial in First-Line Esophageal Squamous Cell Carcinoma
April 23, 2021 08:00 ET
|
Coherus BioSciences, Inc.
REDWOOD CITY, Calif., April 23, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS) has received notice from immuno-oncology partner Junshi Biosciences that the Independent Data...
Coherus Announces Closing of Sale of Common Stock to Immuno-Oncology Partner Junshi Biosciences
April 20, 2021 08:00 ET
|
Coherus BioSciences, Inc.
REDWOOD CITY, Calif., April 20, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced the closing of the sale of Coherus common stock to Junshi Biosciences....
Junshi Biosciences and Coherus BioSciences Announce Initiation of Rolling Submission of BLA for Toripalimab to the U.S. FDA for the Treatment of Nasopharyngeal Carcinoma
March 03, 2021 06:45 ET
|
Coherus BioSciences, Inc.
- BLA submitted with FDA’s breakthrough therapy designation – SHANGHAI, China, and REDWOOD CITY, Calif., March 03, 2021 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd. (“Junshi...
Junshi Biosciences Announces Financial Results for Six Months Ended June 30, 2020 and Provides Corporate Updates
August 30, 2020 20:00 ET
|
Junshi Biosciences
-- Supplemental NDAs for Toripalimab filed-- Expanding into infectious disease and collaborating with IMCAS and Lilly for COVID-19 neutralizing antibodies-- Dual Listing on the STAR Market SHANGHAI,...